| Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one |
62 |
| Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era |
50 |
| Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs |
45 |
| Health benefits of resveratrol: Evidence from clinical studies |
45 |
| Biologically active quinoline and quinazoline alkaloids part I |
42 |
| Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update |
34 |
| Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment |
34 |
| Recent clinical trends in Toll-like receptor targeting therapeutics |
32 |
| Comprehensive review of cardiovascular toxicity of drugs and related agents |
30 |
| JNK signaling in cancer cell survival |
28 |
| Strategies to diversify natural products for drug discovery |
28 |
| Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer |
27 |
| The multifaceted role of autophagy in cancer and the microenvironment |
26 |
| Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules |
25 |
| The Current State of NAD(+)-Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets |
24 |
| A(3) Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy |
24 |
| Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review |
23 |
| Dimethyl fumarate, a two-edged drug: Current status and future directions |
23 |
| Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives |
22 |
| Chitosan-based multifunctional nanomedicines and theranostics for targeted therapy of cancer |
21 |
| Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: Current developments in medicinal chemistry |
20 |
| Selective targeting of antiapoptotic BCL-2 proteins in cancer |
20 |
| Proteases and protease inhibitors in infectious diseases |
20 |
| Biologically active quinoline and quinazoline alkaloids part II |
19 |
| Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A structure-activity relationship perspective |
19 |
| Complex roles of the old drug aspirin in cancer chemoprevention and therapy |
19 |
| Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy |
19 |
| Development of Safe Drugs: The hERG Challenge |
19 |
| Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen |
19 |
| Efflux pump inhibitors of clinically relevant multidrug resistant bacteria |
19 |
| Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study |
18 |
| Therapeutic strategies involving survivin inhibition in cancer |
18 |
| Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives |
18 |
| Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy |
17 |
| The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role |
17 |
| Intramolecular hydrogen bonding: An opportunity for improved design in medicinal chemistry |
17 |
| Progress and challenges in the prevention and control of nonalcoholic fatty liver disease |
17 |
| Toward Hydrogen Sulfide Based Therapeutics: Critical Drug Delivery and Developability Issues |
17 |
| Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges |
17 |
| Antiaging effects of bioactive molecules isolated from plants and fungi |
15 |
| Strategies to target the Hedgehog signaling pathway for cancer therapy |
14 |
| Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update |
13 |
| Antibacterial and beta-Lactamase Inhibitory Activity of Monocyclic beta-Lactams |
13 |
| Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery |
13 |
| Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases |
12 |
| Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target |
12 |
| Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
12 |
| Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential |
12 |
| Carbohydrate-based vaccines for oncotherapy |
11 |
| Lipidic prodrug approach for improved oral drug delivery and therapy |
11 |
